Akèy › Menenjyom
Etid klinik pou Menenjyom ap rekrite nan Etazini
29 etid pou Menenjyom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY8 etid
- Miami, FL8 etid
- Boston, MA7 etid
- Columbus, OH7 etid
- San Francisco, CA6 etid
- Atlanta, GA6 etid
- Jacksonville, FL5 etid
- San Diego, CA5 etid
- Arlington, VA4 etid
- Phoenix, AZ4 etid
- Houston, TX4 etid
- St. Louis, MO4 etid
- Los Angeles, CA4 etid
- Detroit, MI4 etid
- Milwaukee, WI4 etid
- Durham, NC3 etid
- Cincinnati, OH3 etid
- Chicago, IL3 etid
- Grand Rapids, MI3 etid
- Rochester, MN3 etid
- Louisville, KY3 etid
- Cleveland, OH3 etid
- Minneapolis, MN3 etid
- Nashville, TN3 etid
- Cedar Rapids, IA3 etid
- Tampa, FL3 etid
- Baltimore, MD3 etid
- Seattle, WA3 etid
- Omaha, NE3 etid
Pa eta
- Arizona4 etid
- Connecticut3 etid
- Florid8 etid
- Georgia6 etid
- Illinois3 etid
- Indiana3 etid
- Iowa4 etid
- Kalifòni13 etid
- Kentucky4 etid
- Maryland5 etid
- Massachusetts7 etid
- Michigan5 etid
- Minnesota5 etid
- Missouri4 etid
- Nebraska3 etid
- New Hampshire4 etid
- New Jersey3 etid
- New York10 etid
- North Carolina5 etid
- Ohio8 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas5 etid
- Virginia4 etid
- Washington3 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT03180268A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07428616Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06955169UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT04343157Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04374305Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT02523014Natural History Study of Patients With Neurofibromatosis Type 2
Ap rekriteEtid obsèvasyon
Laj 8 a 75 · Tout sèks · Mizajou Sep 1, 2026 · NCT00598351Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06557512Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06014905RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07150806A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07533942Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 22, 2026 · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Ap rekriteFaz 1/2
Laj 4 a 39 · Tout sèks · Mizajou Jul 20, 2026 · NCT05278208Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT07493447Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Jun 10, 2026 · NCT05576103Cognitive Status After Removal of Skull Base Meningioma
Ap rekriteEtid obsèvasyon
Laj 18 a 89 · Tout sèks · Mizajou May 22, 2026 · NCT04635657Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT07418775Cabozantinib for Patients With Recurrent or Progressive Meningioma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 14, 2026 · NCT05425004Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT04082520Abemaciclib in Newly Diagnosed Meningioma Patients
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05940493Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Ap rekriteFaz 4
Laj 18 a 99 · Tout sèks · Mizajou Feb 27, 2026 · NCT06377371Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2026 · NCT04278118Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2026 · NCT06132685Evaluation of the CONVIVO System
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT05139277Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.